Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

PHILADELPHIA, March 19, 2026 — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company’s asset, CT-202, a Nectin-4 x CD3 TCE.

Poster Presentation Details:

Title:

Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202

Abstract Number:

5392

Date and Time:

Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT

Session Category:

Clinical Research

Session:

PO.CL05.12 – Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates

Location:

Poster Section 48

For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. The poster will be made available in the Publications section of the Company’s website at the beginning of the poster session.

About CT-202

CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate (“ADC”), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment.

About Context Therapeutics® Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Investor Relations Contact

Jennifer Minai-Azary Chief Financial Officer Context Therapeutics [email protected]